Skip to main content
SpringerLink
Log in

Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Faderl S, Kantarjian HM (2004) Novel therapies for myelodysplastic syndromes. Cancer 101(2):226–241

    Google Scholar 

  2. Rosenfeld C, List A (2000) A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 14(1):2–8

    Google Scholar 

  3. Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N (2002) Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16(1):1–6

    Google Scholar 

  4. Musto P (2004) Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res 28(4):325–332

    Article  CAS  PubMed  Google Scholar 

  5. Aul C, Giagounidis A, Germing U, Ganser A (2002) Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol 81:485–497

    Google Scholar 

  6. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, Du Randt M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J (2001) Thalidomide produces transfusion independence in long standing refractory anemias of patients with myelodysplastic syndromes. Blood 98(4):958–965

    Google Scholar 

  7. Candoni A, Silvestri F, Buonamici S, Li D, Reddy P, Galili N, Nucifora G, Raza A (2004) Targeted therapies in myelodysplastic syndromes: ASH 2003 Review. Semin Hematol 41(2 Suppl 4):13–20

    Google Scholar 

  8. Raza A, Candoni A, Khan U, Lisak L, Tahir S, Silvestri F, Billmeier J, Imran Alvi M, Mumtaz M, Gezer S, Venugopal P, Reddy P, Galili N (2004) Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 45(10):2099–2104

    Google Scholar 

  9. Raza A, Buonamici S, Lisak L, Tahir S, Li D, Imran M, Chaudary NI, Pervaiz H, Gallegos JA, Alvi MI, Mumtaz M, Gezer S, Venugopal P, Reddy P, Galili N, Candoni A, Singer J, Nucifora G (2004) Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 28(8):791–803

    Google Scholar 

  10. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, Wilkens L, Heinsch M, Willems H, Aivado M, Aul C (2004) Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18(1):113–119

    Google Scholar 

  11. List AF, Kurtin S, Glinsmann-Gibson B, Bellamy W, Buresh A, Mahadevan D, Rimsza L, Waddelton D, Knight RD (2003) Efficacy and safety of CC5013 for treatment of anemia in patients with myelodysplastic syndromes (MDS). Blood 102(11):641

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Haematology and Bone Marrow Transplantation, Department of Medical and Morphological Researches (DMMR), University of Udine, Udine, Italy

    A. Candoni, F. Silvestri, F. Kikic & R. Fanin

  2. Section of Myeloid Diseases and Myelodysplastic Syndromes Center, Rush University, University of Illinois, Chicago, IL, USA

    A. Raza, L. Lisak, N. Galili & M. Mumtaz

Authors
  1. A. Candoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Raza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Silvestri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Lisak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Galili
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Mumtaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Kikic
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R. Fanin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Candoni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Candoni, A., Raza, A., Silvestri, F. et al. Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes. Ann Hematol 84, 479–481 (2005). https://doi.org/10.1007/s00277-005-1031-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-005-1031-7

Keywords

Search

Navigation